Treatment with the FDA-approved ATP6V1A blocker etidronate, a bisphosphonate largely used in osteoporosis treatment [112], decreased levels of the amyotrophic lateral sclerosis associated protein ataxin-2 in cellular models and brains of adult Ataxin-2 mice [111]. The gene discussed is ATXN2; the disease is osteoporosis.